Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Autocrine Signaling01:01

Autocrine Signaling

Autocrine signaling is one of the many signaling mechanisms that function inside multicellular organisms to carry out intercellular communication. In this type of signaling mechanism, the same cell that secretes an extracellular signaling molecule also expresses the receptors to bind and respond to that signaling molecule.
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.

Leukemia·2017
Same author

An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis.

Leukemia·2017
Same author

Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition.

Leukemia·2017
Same author

The cell division control protein 42-Src family kinase-neural Wiskott-Aldrich syndrome protein pathway regulates human proplatelet formation.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin.

Leukemia·2016
Same author

Thrombopoietin receptor is required for the oncogenic function of CALR mutants.

Leukemia·2016

Related Experiment Video

Updated: May 19, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

JAK/STAT signaling in hematological malignancies.

W Vainchenker1, S N Constantinescu

  • 1INSERM, UMR 1009, Hematopoïèse Normale et Pathologique, Villejuif, France. verpre@igr.fr

Oncogene
|August 8, 2012
PubMed
Summary

Mutations in the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway are implicated in hematological malignancies. These genetic alterations can drive disease progression and may be targeted by JAK inhibitors for therapeutic benefit.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is crucial for cytokine receptor signaling, impacting blood formation and immune responses.
  • Dysregulation of the JAK/STAT pathway, including mutations in JAK2 and STAT family members, is linked to various hematological malignancies.
  • Specific mutations like JAK2 V617F and exon 12 mutations are associated with myeloproliferative neoplasms, driving constitutive pathway activation.

Purpose of the Study:

  • To review the role of mutations in the JAK/STAT pathway in hematological malignancies.
  • To discuss how these mutations contribute to disease development, phenotype, and cell survival.
  • To explore the therapeutic potential of JAK inhibitors in treating these cancers.

Main Methods:

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: May 19, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

  • Literature review of studies investigating JAK/STAT pathway mutations in hematological malignancies.
  • Analysis of the impact of specific mutations on disease pathogenesis and clinical outcomes.
  • Discussion of current and potential future therapeutic strategies involving JAK inhibitors.

Main Results:

  • Mutations and overexpression of JAK/STAT pathway components are observed in diverse hematological cancers, including leukemias and lymphomas.
  • Constitutive activation of the JAK/STAT pathway due to mutations confers a proliferative and survival advantage to cancer cells.
  • JAK inhibitors have shown efficacy in treating certain myeloproliferative neoplasms, such as myelofibrosis.

Conclusions:

  • Genetic alterations in the JAK/STAT pathway are significant drivers of hematological malignancies.
  • Targeting the JAK/STAT pathway with inhibitors represents a promising therapeutic avenue for various blood cancers.
  • Combination therapies involving JAK inhibitors may offer enhanced benefits for patients with hematological diseases.